But recent studies have demonstrated conclusively that we can accomplish the same thing—that is, prevent HIV from latching onto CCR5—by editing the CCR5 gene itself. Multiple labs have already pulled this off using CRISPR, at least with cells in a petri dish. But credit for the first success in editing the CCR5 gene in human subjects goes to the ZFN technology and to a California-based company called Sangamo Therapeutics.
